DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR
This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, a cysteine-aspartic protease inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.
1 - 43 . (canceled)
44 . A drug delivery system comprising 1) a CNTF compound, a TNF-α/TNFR inhibitor, or a combination thereof; and 2) a FAS or FASL inhibitor.
45 . The drug delivery system of claim 44 , wherein the CNTF compound is a peptide comprising the amino acid sequence DGGL (SEQ ID NO: 18) or a salt thereof.
46 . The drug delivery system of claim 44 , wherein the CNTF compound is Peptide 6 or Peptide 21.
47 . The drug delivery system of claim 44 , wherein the FAS or FASL inhibitor is bicyclol.
48 . The drug delivery system of claim 44 , wherein the FAS or FASL inhibitor is a peptide comprising the amino acid sequence YLGA (SEQ ID NO: 5) or a salt thereof.
49 . The drug delivery system of claim 48 , wherein the FAS or FASL inhibitor is MET12.
50 . The drug delivery system of claim 48 , wherein the FAS or FASL inhibitor is MET4-8.
51 . The drug delivery system of claim 44 , having about 100 μg to about 1 mg of the CNTF compound, the TNF-α/TNFR inhibitor, or the combination thereof.
52 . The drug delivery system of claim 44 , having about 100 μg to about 1 mg of the FAS or FASL inhibitor.
53 . The drug delivery system of claim 44 , wherein the implant has a weight of about 300 μg to about 10 mg.
54 . The drug delivery system of claim 44 , wherein 1) the CNTF compound, the TNF-α/TNFR inhibitor, or the combination thereof; and 2) the FAS or FASL inhibitor are not covalently bonded to one another.
55 . The drug delivery system of claim 44 , wherein the CNTF compound, the TNF-α/TNFR inhibitor, or the combination thereof is covalently bonded to the FAS or FASL inhibitor.
56 . The drug delivery system of claim 44 , wherein the CNTF compound, the TNF-α/TNFR inhibitor, or the combination thereof is covalently bonded to the sustained delivery component.
57 . The drug delivery system of claim 44 , wherein the FAS or FASL inhibitor is covalently bonded to the sustained delivery component.
58 . A method of treating a medical condition comprising administering a drug delivery system of claim 1 to a mammal in need thereof, wherein the medical condition comprises: 1) an inherited or age-related choroid, retina, or optic nerve disorder or degeneration; 2) an otic disorder; or 3) a neurologic or CNS disorder.
59 . The method of claim 58 , wherein the drug delivery system is injected into an eye of the mammal.
60 . The method of claim 58 , wherein the drug delivery system is injected intra-arterially or intravenously.
61 . The method of claim 58 , wherein the drug delivery system is injected into a ventricle.
62 . The method of claim 58 , wherein the drug delivery system is injected into the central nervous system.
63 . The method of claim 58 , wherein the drug delivery system is injected into the subarachnoid space or into the cerebral spinal fluid.